A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell ...

The promise of CAR-T is undeniable, offering new hope for patients. However, unless the costs are reduced and more patients ...

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...